MX2022013632A - Construcciones de union al antigeno dirigidas a her2 y sus usos. - Google Patents
Construcciones de union al antigeno dirigidas a her2 y sus usos.Info
- Publication number
- MX2022013632A MX2022013632A MX2022013632A MX2022013632A MX2022013632A MX 2022013632 A MX2022013632 A MX 2022013632A MX 2022013632 A MX2022013632 A MX 2022013632A MX 2022013632 A MX2022013632 A MX 2022013632A MX 2022013632 A MX2022013632 A MX 2022013632A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- her2
- binding constructs
- constructs targeting
- targeting her2
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen construcciones de unión al antígeno dirigidas a HER2 y sus usos. Se proporcionan específicamente construcciones de unión al antígeno, un ácido nucleico que las codifican, un vector que comprende dicho ácido nucleico, una célula que comprende dicho vector y una composición farmacéutica que comprende lo anterior. Además se proporcionan sus usos en aspectos tales como el tratamiento de sujetos que padecen tumores que expresan HER2, la destrucción de células tumorales que expresan HER2 o la inhibición del crecimiento de células tumorales que expresan HER2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010365705 | 2020-04-30 | ||
| PCT/CN2021/090794 WO2021219046A1 (zh) | 2020-04-30 | 2021-04-29 | 靶向her2的抗原结合构建体及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013632A true MX2022013632A (es) | 2022-11-16 |
Family
ID=78373353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013632A MX2022013632A (es) | 2020-04-30 | 2021-04-29 | Construcciones de union al antigeno dirigidas a her2 y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230242632A1 (es) |
| EP (1) | EP4144760A1 (es) |
| JP (1) | JP2023523988A (es) |
| KR (1) | KR20230006823A (es) |
| CN (1) | CN115279791A (es) |
| AU (1) | AU2021262322A1 (es) |
| BR (1) | BR112022022036A2 (es) |
| CA (1) | CA3181589A1 (es) |
| IL (1) | IL297662A (es) |
| MX (1) | MX2022013632A (es) |
| TW (1) | TW202142570A (es) |
| WO (1) | WO2021219046A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| AU2014348552A1 (en) * | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
| JP6817064B2 (ja) * | 2013-11-27 | 2021-01-20 | ザイムワークス，インコーポレイテッド | Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| WO2018177967A1 (en) * | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptor formats |
| CA3095093A1 (en) | 2018-04-05 | 2019-10-10 | Novartis Ag | Trispecific binding molecules against cancers and uses thereof |
| CA3188508A1 (en) * | 2020-08-13 | 2022-02-17 | Xiquan Zhang | Antibody drug conjugate |
-
2021
- 2021-04-29 JP JP2022565715A patent/JP2023523988A/ja active Pending
- 2021-04-29 EP EP21797169.6A patent/EP4144760A1/en active Pending
- 2021-04-29 IL IL297662A patent/IL297662A/en unknown
- 2021-04-29 CA CA3181589A patent/CA3181589A1/en active Pending
- 2021-04-29 WO PCT/CN2021/090794 patent/WO2021219046A1/zh unknown
- 2021-04-29 BR BR112022022036A patent/BR112022022036A2/pt unknown
- 2021-04-29 AU AU2021262322A patent/AU2021262322A1/en active Pending
- 2021-04-29 CN CN202180020300.4A patent/CN115279791A/zh active Pending
- 2021-04-29 MX MX2022013632A patent/MX2022013632A/es unknown
- 2021-04-29 TW TW110115652A patent/TW202142570A/zh unknown
- 2021-04-29 KR KR1020227038531A patent/KR20230006823A/ko active Search and Examination
- 2021-04-29 US US17/922,230 patent/US20230242632A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202142570A (zh) | 2021-11-16 |
| AU2021262322A1 (en) | 2022-12-08 |
| BR112022022036A2 (pt) | 2022-12-13 |
| EP4144760A1 (en) | 2023-03-08 |
| WO2021219046A1 (zh) | 2021-11-04 |
| US20230242632A1 (en) | 2023-08-03 |
| JP2023523988A (ja) | 2023-06-08 |
| IL297662A (en) | 2022-12-01 |
| CN115279791A (zh) | 2022-11-01 |
| KR20230006823A (ko) | 2023-01-11 |
| AU2021262322A9 (en) | 2023-06-29 |
| CA3181589A1 (en) | 2021-11-04 |
| EP4144760A9 (en) | 2023-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091486A1 (ru) | Способы и композиции для поляризации макрофагов | |
| PH12020550860A1 (en) | Anti-trem2 antibodies and related methods | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| EA201790986A1 (ru) | Антитела к cd73 и их применения | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| CR20220136A (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| MX2021001508A (es) | Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso. | |
| WO2019090148A3 (en) | Compositions and methods related to therapeutic cell systems for tumor growth inhibition | |
| HK1126818A1 (en) | Modified recombinant vaccinia viruses, uses thereof | |
| WO2007039192A3 (en) | Compositions and methods for treating tumors presenting survivin antigens | |
| AU2019415848A8 (en) | Claudin18.2 binding moieties and uses thereof | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| PH12020550035A1 (en) | Universal abt compounds and uses thereof | |
| MX2021013844A (es) | Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. | |
| MX2020010701A (es) | Péptidos antigénicos para la prevención y el tratamiento del cáncer. | |
| MX2020011487A (es) | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. | |
| WO2019241893A3 (en) | Anti-her3 antibody and uses thereof | |
| MX2022007849A (es) | Anticuerpos especificos contra la claudina 18.2 tumoral. | |
| WO2021094562A3 (en) | Antigenic peptides for prevention and treatment of b-cell malignancy | |
| WO2022081718A8 (en) | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof | |
| WO2003100000A3 (en) | Amplification and overexpression of oncogenes | |
| MX2023008809A (es) | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. | |
| WO2022232016A3 (en) | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof | |
| MX2019002664A (es) | Proteina de union a antigeno contra her3. |